BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6974052)

  • 1. Immunosuppression by 2' deoxycoformycin: studies on the mode of administration.
    Sordillo EM; Ikehara S; Good RA; Trotta PP
    Cell Immunol; 1981 Sep; 63(2):259-71. PubMed ID: 6974052
    [No Abstract]   [Full Text] [Related]  

  • 2. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
    Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
    Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
    Ratech H; Thorbecke GJ; Hirschhorn R
    Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of deoxycoformycin in mice. III. A murine model reproducing multi-system pathology of human adenosine deaminase deficiency.
    Ratech H; Hirschhorn R; Thorbecke GJ
    Am J Pathol; 1985 Apr; 119(1):65-72. PubMed ID: 3872599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune function in mice exposed to the adenosine deaminase inhibitor 2'-deoxycoformycin during immune system development.
    Luebke RW; Lawson LD; Rogers RR; Riddle MM; Smialowicz RJ
    Immunopharmacol Immunotoxicol; 1987; 9(2-3):149-61. PubMed ID: 3501794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
    Earle MF; Glazer RI
    Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
    [No Abstract]   [Full Text] [Related]  

  • 7. Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin.
    Checkik BE; Perets A; SenGupta S; Fernandes B
    J Natl Cancer Inst; 1983 Nov; 71(5):999-1010. PubMed ID: 6358608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
    Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
    Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
    Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
    J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Luebke RW; Lawson LD; Rogers RR; Riddle MM; Rowe DG; Smialowicz RJ
    Immunopharmacology; 1987 Feb; 13(1):25-35. PubMed ID: 2952620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
    Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
    Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of interleukin-2 messenger RNA in mouse lymphocytes by 2'-deoxycoformycin and adenosine metabolites.
    Cohen MB; Glazer RI
    Ann N Y Acad Sci; 1985; 451():180-7. PubMed ID: 3878116
    [No Abstract]   [Full Text] [Related]  

  • 13. Animal model for immune dysfunction associated with adenosine deaminase deficiency.
    Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical consequences of treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Paine RM; Smyth JF; Harrap KR
    Adv Exp Med Biol; 1979; 122B():365-71. PubMed ID: 317569
    [No Abstract]   [Full Text] [Related]  

  • 15. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pentostatin (2'deoxycoformycin), an inhibitor of adenosine deaminase, on type II collagen-induced arthritis in rats.
    Gilbertsen RB
    J Immunopharmacol; 1985; 7(3):325-41. PubMed ID: 3877119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 2'-deoxycoformycin infusion on S-adenosylhomocysteine hydrolase and the amount of S-adenosylhomocysteine and related compounds in tissues of mice.
    Helland S; Ueland PM
    Cancer Res; 1983 Sep; 43(9):4142-7. PubMed ID: 6603264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 2'-deoxycoformycin infusion on mouse adenosine deaminase.
    Tedde A; Balis ME; Schonberg R; Trotta PP
    Cancer Res; 1979 Aug; 39(8):3044-50. PubMed ID: 455289
    [No Abstract]   [Full Text] [Related]  

  • 19. [Modulation of graft versus host disease by in vitro incubation of donor cells with deoxycoformycin and deoxyadenosine].
    Schofer O; Veit BC
    Immun Infekt; 1987 Sep; 15(5):186-90. PubMed ID: 3315974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.